BioSenic SA

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Despite the groundbreaking potential of cell and gene therapy (CGT), and like many other new technologies, the CGT space faces significant challenges that hinder its progress. At the June 2023 Interna

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial